Please login to the form below

Not currently logged in
Email:
Password:

Diabetes drugs exhibit equal risk

A US-based study of 30,000 diabetics shows the same percentage risk of heart attack and heart failure associated with Avandia and Actos

A US-based study, which analysed prescribing data for approximately 30,000 patients with type 2 diabetes (average age 54), has found that the risk of heart attacks or death after taking the glucose-lowering diabetes drugs Avandia (rosiglitazone) and Actos (pioglitazone) are about the same.

These latest findings contradict the conclusions of several previous studies that showed elevated cardiovascular risks associated with GSK's Avandia, but not for Actos by Takeda. It also supports the findings of some others; adding further to the ongoing debate and confusion surrounding the safety of the class of drugs known as thiazolidinediones.

In July 2010 the US Food and Drug Administration (FDA) advisory panel recommended Avandia carry a second black-box warning of the cardiac dangers on its label. No such recommendation was made for Actos.

Yet, according to this latest study, published August 24 in Circulation: Cardiovascular Quality and Outcome, the risk of a heart attack, heart failure or dying stayed in the vicinity of 4 per cent for those studied, over a period just short of three years, no matter which medication the patient was taking.

"Our study looked at a population of commercially insured patients so these potentially could represent healthier and younger patients," said study lead author Debra Wertz. Wertz is the outcomes research manager for HealthCore, the research subsidiary of the insurance company WellPoint, which funded the study.

25th August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics